The 3 Critical Reasons Eli Lilly’s Stock Is Stumbling Against Novo’s Oral Wegovy
The race for dominance in the lucrative obesity drug market has taken a dramatic turn. Eli Lilly, a titan in the weight-loss pharmaceutical arena, recently faced a significant setback with the clinical trial data release for its oral obesity drug, orforglipron. Despite a promising future, the immediate reaction was a stark 13% drop in stock price, highlighting…